The caveolin proteins

Genome Biology

Volumn 5, Issue 3, 2004, Pages

  Williams, Terence M ^a   Lisanti, Michael P ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAVEOLIN; CAVEOLIN 1; CAVEOLIN 2; CAVEOLIN 3; CHOLESTEROL;

ADIPOCYTE; AMINO ACID SEQUENCE; CAENORHABDITIS ELEGANS; CANCER INHIBITION; CAVEOLA; CELL DIFFERENTIATION; CELL MEMBRANE; CELL TYPE; CHROMOSOME 7Q; ENDOTHELIUM CELL; GENE MAPPING; HEART MUSCLE CELL; HOMEOSTASIS; INTRACELLULAR TRANSPORT; LUNG ALVEOLUS CELL; MULTIGENE FAMILY; MUSCLE CELL; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; PUFFER FISH; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; SMOOTH MUSCLE FIBER; VERTEBRATE; XENOPUS LAEVIS;

ANIMALS; CAVEOLINS; HUMANS;

ANIMALIA; CAENORHABDITIS; CAENORHABDITIS ELEGANS; MAMMALIA; TAKIFUGU; TAKIFUGU RUBRIPES; VERTEBRATA; XENOPUS LAEVIS;

EID: 11144354850     PISSN: 14656906     EISSN: None     Source Type: Journal    
DOI: 10.1186/gb-2004-5-3-214     Document Type: Review

References (90)

1. Palade GE: Fine structure of blood capillaries. J Appl Phys 1953, 24:1424-1436.
2. Rothberg KG, Heuser JE, Donzell WC, Ying YS, Glenney JR, Anderson RG: Caveolin, a protein component of caveolae membrane coats. Cell 1992, 68:673-682.
3. Kurzchalia TV, Dupree P, Parton RG, Kellner R, Virta H, Lehnert M, Simons K: VIP 21, A 21-kDa membrane protein is an integral component of trans-Golgi-network-derived transport vesicles. J Cell Biol 1992, 118:1003-1014.
4. Glenney JR Jr, Zokas L: Novel tyrosine kinase substrates from Rous sarcoma virus-transformed cells are present in the membrane skeleton. J Cell Biol 1989, 108:2401-2408.
5. Glenney, JR Jr, Soppet D: Sequence and expression of caveolin, a protein component of caveolae plasma membrane domains phosphorylated on tyrosine in Rous sarcoma virus-transformed fibroblasts. Proc Natl Acad Sci USA 1992, 89:10517-10521.
6. Scherer PE, Okamoto T, Chun M, Nishimoto I, Lodish HF, Lisanti MP: Identification, sequence and expression of caveolin-2 defines a caveolin gene family. Proc Natl Acad Sci USA 1996, 93:131-135.
7. Scherer PE, Lewis RY, Volonte D, Engelman JA, Galbiati F, Couet J, Kohtz DS, van Donselaar E, Peters P, Lisanti MP: Cell-type and tissue-specific expression of caveolin-2. Caveolins 1 and 2 co-localize and form a stable hetero-oligomeric complex in vivo. J Biol Chem 1997, 272:29337-29346.
8. Parolini I, Sargiacomo M, Galbiati F, Rizzo G, Grignani F, Engelman JA, Okamoto T, Ikezu T, Scherer PE, Mora R, et al.: Expression of caveolin-1 is required for the transport of caveolin-2 to the plasma membrane. Retention of caveolin-2 at the level of the Golgi complex. J Biol Chem 1999, 274:25718-25725.
9. Tang Z, Scherer PE, Okamoto T, Song K, Chu C, Kohtz DS, Nishimoto I, Lodish HF, Lisanti MP: Molecular cloning of caveolin-3, a novel member of the caveolin gene family expressed predominantly in muscle. J Biol Chem 1996, 271:2255-2261.
10. Way M,AParton R: M-caveolin: a muscle-specific caveolin-related protein. FEBS Lett 1995, 376:108-112.
11. Tang Z, Okamoto T, Boontrakulpoontawee P, Katada T, Otsuka AJ, Lisanti MP: Identification, sequence, and expression of an invertebrate caveolin gene family from the nematode Caenorhabditis elegans: Implications for the molecular evolution of mammalian caveolin genes. J Biol Chem 1997, 272:2437-2445.
12. Scheel J, Srinivasan J, Honnert U, Henske A, Kurzchalia TV: Involvement of caveolin-1 in meiotic cell-cycle progression in Caenorhabditis elegans. Nat Cell Biol 1999, 1:127-129.
13. Engelman JA, Zhang XL, Lisanti MP: Sequence and detailed organization of the human caveolin-1 and -2 genes located near the D7S522 locus (7q31.1). Methylation of a CpG island in the 5′ promoter region of the caveolin-1 gene in human breast cancer cell lines. FEBS Lett 1999, 448:221-230.
14. Engelman JA, Zhang XL, Lisanti MP: Genes encoding human caveolin-1 and -2 are co-localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers. FEBS Lett 1998, 436:403-410.
15. Scherer PE, Tang Z, Chun M, Sargiacomo M, Lodish HF, Lisanti MP: Caveolin isoforms differ in their amino-terminal protein sequence and subcellular distribution: Identification and epitope mapping of an isoform-specific monoclonal antibody probe. J Biol Chem 1995, 270:16395-16401.
16. Sargiacomo M, Scherer PE, Tang Z, Kubler E, Song KS, Sanders MC, Lisanti MP: Oligomeric sIructure of caveolin: implications for caveolae membrane organization. Proc Natl Acad Sci USA 1995, 92:9407-9411.
17. Dietzen DJ, Hastings WR, Lublin DM: Caveolin is palmitoylated on multiple cysteine residues: Palmitoylation is not necessary for localization of caveolin to caveolae. J Biol Chem 1995, 270:6838-6842.
18. Li S, Seitz R, Lisanti MP: Phosphorylation of caveolin by Src tyrosine, kinases: The α-isoform of caveolin is selectively phosphorylated by v-Src in vivo. J Biol Chem 1996, 271:3863-3868.
19. Lee H, Volonte D, Galbiati F, Iyengar P, Lublin DM, Bregman DB, Wilson MT, Campos-Gonzalez R, Bouzahzah B, Pestell RG, et al.: Constitutive and growth factor-regulated phosphorylation of caveolin-1 occurs at the same site (Tyr-14) in vivo: Identification of a c-Src/Cav- 1/Grb7 signaling cassette. Mol Endocrinol 2000, 14:1750-1775.
20. Monier S, Parton RG, Vogel F, Behike J, Henske A, Kurzchalia TV: VIP21-caveolin, a membrane protein constituent of the caveolar coat, oligomerizes in vivo and in vitro. Mol Biol Cell 1995, 6:911-927.
21. Simons K, Toomre D: Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 2000, 1:31-39.
22. Brown DA, London E: Functions of lipid rafts in biological membranes. Ann Rev Cell Dev Biol 1998, 14:111-136.
23. Galbiati F, Razani B, Lisanti MP: Emerging themes in lipid rafts and caveolae. Cell 2001, 106:403-411.
24. Liu J, Oh P, Horner T, Rogers RA, Schnitzer JE: Organized endothelial cell surface signal transduction in caveolae distinct from glycosylphosphatidylinositol-anchored protein microdomains. J Biol Chem 1997, 272:7211-7222.
25. Sargiacomo M, Sudol M, Tang Z, Lisanti MP: Signal transducing molecules and GPI-linked proteins form a caveolin-rich insoluble complex in MDCK cells. J Cell Biol 1993, 122:789-807.
26. Lisanti MP, Scherer PE, Vidugiriene J, Tang Z, Hermanowski-Vosatka A, Tu YH, Cook RF, Sargiacomo M: Characterization of caveolin-rich membrane domains isolated from an endothelial-rich source: implications for human disease. J Cell Biol 1994, 126:111-126.
27. Lisanti MP, Scherer PE, Tang Z, Sargiacomo M: Caveolae, caveolin and caveolin-rich membrane domains: A signalling hypothesis. Trends Cell Biol 1994, 4:231-235.
28. Lisanti MP, Tang Z, Scherer PE, Sargiacomo M: Caveolae purification and GPI-linked protein sorting in polarized epithelia. Meth Enzymol 1995, 250:655-668.
29. Lisanti MP, Sargiacomo M, Scherer PE: Purification of caveolae-derived membrane microdomains containing lipid-anchored signaling molecules, such as GPI-anchored proteins, H-Ras, Src- family tyrosine kinases, eNOS, and G-protein alpha-, beta-, and gamma- subunits. Methods Mol Biol 1999, 116:51-60.
30. Chang WJ, Ying YS, Rothberg KG, Hooper NM, Turner AJ, Gambliel HA, De Gunzburg J, Mumby SM, Gilman AG, Anderson RG: Purification and characterization of smooth muscle cell caveolae. J Cell Biol 1994, 126:127-38.
31. Schlegel A, Lisanti MP: A molecular dissection of caveolin-1 membrane attachment and oligomerization. Two separate regions of the caveolin-1 carboxy-terminal domain mediate membrane binding and oligomer/oligomer interactions in vivo. J Biol Chem 2000, 275:21605-21617.
32. Liu P, Rudick M, Anderson RG: Multiple functions of caveolin-1. J Biol Chem 2002, 277:41295-41298.
33. Li WP, Liu P, Pilcher BK, Anderson RG: Cell-specific targeting of caveolin-1 to caveolae, secretory vesicles, cytoplasm or mitochondria. J Cell Sci 2001, 114:1397-1408.
34. Song KS, Scherer PE, Tang Z, Okamoto T, Li S, Chafel M, Chu C, Kohtz DS, Lisanti MP: Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells. Caveolin-3 is a component of the sarcolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins. J Biol Chem 1996, 271:15160-15165.
35. Razani B, Engelman JA, Wang XB, Schubert W, Zhang XL, Marks CB, Macaluso F, Russell RG, Li M, Pestell RG, et al.: Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem 2001, 276:38121-38138.
36. Razani B, Combs TP, Wang XB, Frank PG, Park DS, Russell RG, Li M, Tang B, Jelicks LA, Scherer PE, Lisanti MP: Caveolin-1-deficient mice are lean, resistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte abnormalities. J Biol Chem 2002, 277:8635-8647.
37. Razani B, Wang XB, Engelman JA, Battista M, Lagaud G, Zhang XL, Kneitz B, Hou H Jr, Christ GJ, Edelmann W, Lisanti MP: Caveolin-2-deficient mice show evidence of severe pulmonary dysfunction without disruption of caveolae. Mol Cell Biol 2002, 22:2329-2344.
38. Drab M, Verkade P, Elger M, Kasper M, Lohn M, Lauterbach B, Menne J, Lindschau C, Mende F, Luft FC, et al.: Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 2001, 293:2449-2452.
39. Woodman SE, Cheung MW, Tarr M, North AC, Schubert W, Lagaud G, Marks CB, Russell RG, Hassan GS, Factor SM, et al.: Urogenital alterations in aged male caveolin-1 knock-out mice. J Urol 2004, 171:950-957.
40. Galbiati F, Engelman JA, Volonte D, Zhang XL, Minetti C, Li M, Hou H Jr, Kneitz B, Edelmann W, Lisanti MP: Caveolin-3 null mice show a loss of caveolae, changes in the microdomain distribution of the dystrophin-glycoprotein complex, and T-tubule abnormalities. J Biol Chem 2001, 276:21425-21433.
41. Woodman SE, Park DS, Cohen AW, Cheung MW, Chandra M, Shirani J, Tang B, Jelicks LA, Kitsis RN, Christ GJ, et al.: Caveolin-3 knock-out mice develop a progressive cardiomyopathy and show hyperactivation of the p42/44 MAPK cascade. J Biol Chem 2002, 277:38988-38997.
42. RazaFi B, Woodman SE, Lisanti MP: Caveolae: from cell biology to animal physiology. Pharmacol Rev 2002, 54:431-467.
43. Razani B, Lisanti MI: Caveolin-deficient mice: insights into caveolar function and human disease. J Clin Invest 2001, 108:1553-1561
44. Hayashi K, Matsuda S, Machida K, Yamamoto T, Fukuda Y, Nimura Y, Hayakawa T, Hamaguchi M: Invasion activating caveolin-1 mutation in human scirrhous breast cancers. Cancer Res 2001, 61:2361-2364.
45. Lee H, Park DS, Razani B, Russell RG, Pestell RG, Lisanti MP: Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: Caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1 (-/-) null mice show mammary epithelial cell hyperplasia. Am J Pathol 2002, 161:1357-1369.
46. Minetti C, Sotgia F, Bruno C, Scartezzini P, Broda P, Bado M, Masetti E, Mazzocco M, Egeo A, Donati MA, et al.: Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat Genet 1998, 18:365-368.
47. Galbiati F, Volonte D, Minetti C, Chu JB, Lisanti MP: Phenotypic behavior of caveolin-3 mutations that cause autosomal dominant limb girdle muscular dystrophy (LGMD-IC). Retention of LGMD-IC caveolin-3 mutants within the Golgi complex. J Biol Chem 1999, 274:25632-25641.
48. Galbiati F, Volonte D, Minetti C, Bregman DB, Lisanti MP: Limb-girdle muscular dystrophy (LGMD-IC) mutants of caveolin-3 undergo ubiquitination and proteasomal degradation. Treatment with proteasomal inhibitors blocks the dominant negative effect of LGMD-IC mutants and rescues wild-type caveolin-3. J Biol Chem 2000, 275:37702-37711.
49. Galbiati F, Razani B, Lisanti MP: Caveolae and caveolin-3 in muscular dystrophy. Trends Mol Med 2001, 7:435-441.
50. Parton RG, Way M, Zorzi N, Stang E: Caveolin-3 associates with developing T-tubules during muscle differentiation. J Cell Biol 1997, 136:137-154.
51. Minetti C, Bado M, Broda P, Sotgia F, Bruno C, Galbiati F, Volonte D, Lucania G, Pavan A, Bonilla E, Lisanti MP, Cordone G: Impairment of caveolae formation and T-system disorganization in human muscular dystrophy with caveolin-3 deficiency. Am J Pathol 2002, 160:265-270.
52. Pelkmans L, Helenius A: Endocytosis via caveolae. Traffic 2002, 3:311-320.
53. Schnitzer JE, Liu J, Oh P: Endothelial caveolae have the molecular transport machinery for vesicle budding, docking, and fusion including VAMP, NSF, SNAP, annexins, and GTPases. J Biol Chem 1995, 270:14399-14404.
54. Oh P, McIntosh DP, Schnitzer JE: Dynamin at the neck of caveolae mediates their budding to form transport vesicles by GTP-driven fission from the plasma membrane of endothelium. J Cell Biol 1998, 141:101-114.
55. Henley JR, Krueger EW, Oswald BJ, McNiven MA: Dynamin-mediated internalization of caveolae. J Cell Biol 1998, 141:85-99.
56. Montesano R, Roth J, Robert A, Ord L: Non-coated membrane invaginations are involved in binding and internalization of cholera and tetanus toxins. Nature 1982, 296:651-653.
57. Sotgia F, Razani B, Bonuccelli G, Schubert W, Battista M, Lee H, Capozza F, Schubert AL, Minetti C, Buckley JT, Lisanti MP: Intracellular retention of GPI-linked proteins in caveolin-deficient cells. Mol Cell Biol 2002, 22:3905-3926.
58. Norkin LC: Caveolae in the uptake and targeting of infectious agents and secreted toxins. Adv Drug Deliv Rev 2001, 49:301-315.
59. Murata M, Peranen J, Schreiner R, Wieland F, Kurzchalia TV, Simons K: VIP21/caveolin is a cholesterol-binding protein. Proc Natl Acad Sci USA 1995, 92:10339-10343.
60. Li S, Song KS, Lisanti MP: Expression and characterization of recombinant caveolin: Purification by poly-histidine tagging and cholesterol-dependent incorporation into defined lipid membranes. J Biol Chem 1996, 271:568-573.
61. Smart EJ, Anderson RG: Alterations in membrane cholesterol that affect structure and function of caveolae. Methods Enzymol 2002, 353:131-139.
62. Hailstones D, Sleer LS, Parton RG, Stanley KK: Regulation of caveolin and caveolae by cholesterol in MDCK cells. J Lipid Res 1998, 39:369-79.
63. Roy S, Luetterforst R, Harding A, Apolloni A, Etheridge M, Stang E, Rolls B, Hancock JF, Parton RG: Dominant-negative caveolin inhibits H-Ras function by disrupting cholesterol-rich plasma membrane domains. Nat Cell Biol 1999, 1:98-105.
64. Bist A, Fielding PE, Fielding CJ: Two sterol regulatory element-like sequences mediate up-regulation of caveolin gene transcription in response to low-density lipoprotein free cholesterol. Proc Natl Acad Sci USA 1997, 94:10693-10698.
65. Smart EJ, Ying Y, Donzell WC, Anderson RG: A role for caveolin in transport of cholesterol from endoplasmic reticulum to plasma membrane. J Biol Chem 1996, 271:29427-29435.
66. Pol A, Luetterforst R, Lindsay M, Heino S, Ikonen E, Parton RG: A caveolin dominant negative mutant associates with lipid bodies and induces intracellular cholesterol imbalance. J Cell Biol 2001, 152:1057-1070.
67. Fielding PE, Fielding CJ: Plasma membrane caveolae mediate the efflux of cellular free cholesterol. Biochemistry 1995, 34:14288-14292.
68. Arakawa R, Abe-Dohmae S, Asai M, Ito JI, Yokoyama S: Involvement of caveolin-1 in cholesterol enrichment of high density lipoprotein during its assembly by apolipoprotein and THP-1 cells. J Lipid Res 2000, 41:1952-1962.
69. Frank PG, Pedraza A, Cohen DE, Lisanti MP: Adenovirus-mediated expression of caveolin-1 in mouse liver increases plasma high-density lipoprotein levels. Biochemistry 2001, 40:10892-10900.
70. Babitt J, Trigatti B, Rigotti A, Smart EJ, Anderson RG, Xu S, Krieger M: Murine SR-BI, a high density lipoprotein receptor that mediates selective lipid uptake, is amino-glycosylated and fatty acylated and colocalizes with plasma membrane caveolae. J Biol Chem 1997, 272:13242-13249.
71. Fielding CJ, Fielding PE: Caveolae and intracellular trafficking of cholesterol. Adv Drug Deliv Rev 2001, 49:251-264.
72. Li S, Couet J, Lisanti MP: Src tyrosine kinases, G alpha subunits and H-Ras share a common membrane-anchored scaffolding protein, Caveolin. Caveolin binding negatively regulates the auto-activation of Src tyrosine kinases. J Biol Chem 1996, 271:29182-29190.
73. Couet J, Li S, Okamoto T, Ikezu T, Lisanti MP: Identification of peptide and protein ligands for the caveolin-scaffolding domain. Implications for the interaction of caveolin with caveolae-associated proteins. J Biol Chem 1997, 272:6525-6533.
74. Couet J, Sargiacomo M, Lisanti MP: Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities. J Biol Chem 1997, 272:30429-30438.
75. Huang C, Hepler JR, Chen LT, Gilman AG, Anderson RG, Mumby SM: Organization of G proteins and adenylyl cyclase at the plasma membrane. Mol Biol Cell 1997, 8:2365-2378.
76. Feron O, Belhassen L, Kobzik L, Smith TW, Kelly RA, Michel T: Endothelial nitric oxide synthase targeting to caveolae. Specific interactions with caveolin isoforms in cardiac myocytes and endothelial cells. J Biol Chem 1996, 271:22810-22814.
77. Rybin VO, Xu X, Lisanti MP, Steinberg SF: Differential targeting of beta -adrenergic receptor subtypes and adenylyl cyclase to cardiomyocyte caveolae. A mechanism to functionally regulate the cAMP signaling pathway. J Biol Chem 2000, 275:41447-41457.
78. Rybin VO, Xu X, Steinberg SF: Activated protein kinase C isoforms target to cardiomyocyte caveolae: Stimulation of local protein phosphorylation. Circ Res 1999, 84:980-988.
79. Sotgia F, Lee JK, Das K, Bedford M, Petrucci TC, Macioce P, Sargiacomo M, Bricarelli FD, Minetti C, Sudol M, Lisanti MP: Caveolin-3 directly interacts with the carboxy-terminal tail of beta-dystroglycan. Identification of a central WW-like domain within caveolin family members. J Biol Chem 2000, 275:38048-38058.
80. Glenney JR Jr: Tyrosine phosphorylation of a 22-kDa protein is correlated with transformation by Rous sarcoma virus. J Biol Chem 1989, 264:20163-20166.
81. Koleske AJ, Baltimore D, and Lisanti MP: Reduction of caveolin and caveolae in oncogenically transformed cells. Proc Natl Acad Sci USA 1995, 92:1381-1385.
82. Engelman JA, Wykoff CC, Yasuhara S, Song KS, Okamoto T, Lisanti MP: Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth. J Biol Chem 1997, 272:16374-16381.
83. Sager R, Sheng S, Anisowicz A, Sotiropoulou G, Zou Z, Stenman G, Swisshelm K, Chen Z, Hendrix MJ, Pemberton P, et al.: RNA genetics of breast cancer: Maspin as a paradigm. Cold Spring Harbor Sym Quant Biol 1994, 59:537-546.
84. Lee SW, Reimer CL, Oh P, Campbell DB, Schnitzer JE: Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene 1998, 16:1391-1397.
85. Engelman JA, Chu C, Lin A, Jo H, Ikezu T, Okamoto T, Kohtz DS, Lisanti MP: Caveolin-mediated regulation of signaling along the p42/44 MAP kinase cascade in vivo. A role for the caveolin-scaffolding domain. FEBS Lett 1998, 428:205-211.
86. Galbiati F, Volonte D, Engelman JA, Scherer PE, Lisanti MP: Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO J 1998, 17:6633-6648.
87. Hulit J, Bash T, Fu M, Galbiati F, Albanese C, Sage DR, Schlegel A, Zhurinsky J, Shtutman M, Ben-Ze'ev A, Lisanti MP, Pestell RG: The cyclin D1 gene is transcriptionally repressed by caveolin-1. J Biol Chem 2000, 275:21203-21209.
88. Williams TM, Cheung MW, Park DS, Razani B, Cohen AW, Muller WJ, Di Vizio D, Chopra NG, Pestell RG, Lisanti MP: Loss of caveolin-1 gene expression accelerates the development of dysplastic mammary lesions in tumor-prone transgenic mice. Mol Biol Cell 2003, 14:1027-1042.
89. Capozza F, Williams TM, Schubert W, McClain S, Bouzahzah B, Sotgia F, Lisanti MP: Absence of caveolin-1 sensitizes mouse skin to carcinogen-induced epidermal hyperplasia and tumor formation. Am J Pathol 2003, 162:2029-2039.
90. Park DS, Lee H, Frank PG, Razani B, Nguyen AV, Parlow AF, Russell RG, Hulit J, Pestell RG, Lisanti MP: Caveolin-1-deficient mice show accelerated mammary gland development during pregnancy, premature lactation, and hyperactivation of the Jak-2/STAT5a signaling cascade. Mol Biol Cell 2002, 13:3416-3430.